{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sham+IVT",
    "query": {
      "intervention": "Sham IVT"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 53,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sham+IVT&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T04:48:16.295Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02484690",
      "title": "A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Faricimab",
          "type": "DRUG"
        },
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Sham Procedure",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 273,
      "start_date": "2015-08-11",
      "completion_date": "2017-09-26",
      "has_results": true,
      "last_update_posted_date": "2020-11-12",
      "last_synced_at": "2026-09-03T04:48:16.295Z",
      "location_count": 52,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 46 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02484690"
    },
    {
      "nct_id": "NCT05850520",
      "title": "A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Edema Secondary to Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg",
          "type": "DRUG"
        },
        {
          "name": "Sham",
          "type": "DRUG"
        },
        {
          "name": "Fluorescein",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 892,
      "start_date": "2023-05-15",
      "completion_date": "2025-05-27",
      "has_results": true,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-09-03T04:48:16.295Z",
      "location_count": 53,
      "location_summary": "Fullerton, California • Long Beach, California • Mountain View, California + 48 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05850520"
    },
    {
      "nct_id": "NCT03038880",
      "title": "Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascularization, Choroidal",
        "Macular Degeneration, Age-Related"
      ],
      "interventions": [
        {
          "name": "Faricimab",
          "type": "DRUG"
        },
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Sham Procedure",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2017-01-27",
      "completion_date": "2018-03-29",
      "has_results": true,
      "last_update_posted_date": "2021-01-05",
      "last_synced_at": "2026-09-03T04:48:16.295Z",
      "location_count": 25,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 22 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03038880"
    },
    {
      "nct_id": "NCT04188015",
      "title": "Study of ANX007 in Participants With Primary Open-angle Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "2.5mg ANX007",
          "type": "BIOLOGICAL"
        },
        {
          "name": "5.0mg ANX007",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sham Procedure",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Annexon, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2018-07-25",
      "completion_date": "2019-06-03",
      "has_results": false,
      "last_update_posted_date": "2020-08-20",
      "last_synced_at": "2026-09-03T04:48:16.295Z",
      "location_count": 2,
      "location_summary": "Newport Beach, California • Stanford, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04188015"
    },
    {
      "nct_id": "NCT05642312",
      "title": "A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Uveitic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Vamikibart",
          "type": "DRUG"
        },
        {
          "name": "Sham",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 245,
      "start_date": "2023-01-09",
      "completion_date": "2025-07-09",
      "has_results": false,
      "last_update_posted_date": "2025-11-21",
      "last_synced_at": "2026-09-03T04:48:16.295Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Lakewood, Colorado • St. Petersburg, Florida + 13 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Hagerstown",
          "state": "Maryland"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05642312"
    },
    {
      "nct_id": "NCT04656561",
      "title": "A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Geographic Atrophy"
      ],
      "interventions": [
        {
          "name": "ANX007",
          "type": "DRUG"
        },
        {
          "name": "Sham comparator",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Annexon, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 270,
      "start_date": "2021-02-26",
      "completion_date": "2023-09-13",
      "has_results": false,
      "last_update_posted_date": "2024-08-21",
      "last_synced_at": "2026-09-03T04:48:16.295Z",
      "location_count": 45,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 39 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04656561"
    },
    {
      "nct_id": "NCT02398500",
      "title": "Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Age-related Macular Degeneration (AMD)"
      ],
      "interventions": [
        {
          "name": "LMG324",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ranibizumab 0.5 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sham",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2015-07-22",
      "completion_date": "2016-05-20",
      "has_results": false,
      "last_update_posted_date": "2019-06-05",
      "last_synced_at": "2026-09-03T04:48:16.295Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02398500"
    },
    {
      "nct_id": "NCT05383209",
      "title": "Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonproliferative Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "EYP-1901",
          "type": "DRUG"
        },
        {
          "name": "Sham IVT",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "EyePoint Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 77,
      "start_date": "2022-09-28",
      "completion_date": "2024-05-06",
      "has_results": true,
      "last_update_posted_date": "2025-08-15",
      "last_synced_at": "2026-09-03T04:48:16.295Z",
      "location_count": 36,
      "location_summary": "Phoenix, Arizona • Huntington Beach, California • Oxnard, California + 33 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05383209"
    },
    {
      "nct_id": "NCT06659445",
      "title": "Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Geographic Atrophy (GA)",
        "Age - Related Macular Degeneration (AMD)"
      ],
      "interventions": [
        {
          "name": "ONL1204 Opthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Avacincaptad Pegol intravitreal solution",
          "type": "DRUG"
        },
        {
          "name": "Sham",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "ONL Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 324,
      "start_date": "2025-10-28",
      "completion_date": "2028-11",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-09-03T04:48:16.295Z",
      "location_count": 53,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 48 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06659445"
    },
    {
      "nct_id": "NCT04432831",
      "title": "A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Faricimab",
          "type": "DRUG"
        },
        {
          "name": "Sham Procedure",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1479,
      "start_date": "2020-08-05",
      "completion_date": "2023-10-11",
      "has_results": true,
      "last_update_posted_date": "2026-02-09",
      "last_synced_at": "2026-09-03T04:48:16.295Z",
      "location_count": 119,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 105 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04432831"
    }
  ]
}